Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma

Cancer

Volumn 110, Issue 1, 2007, Pages 129-137

  Jun, Yong Park ^a,b   Sang, Hoon Ahn ^a,b   Young, Joon Yoon ^a,b   Ja, Kyung Kim ^a,b   Hyun, Woong Lee ^a,b   Do, Yun Lee ^a,b   Chae, Yoon Chon ^a,b   Young, Myoung Moon ^a,b   Han, Kwang Hyub ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei Liver Cancer Special Clinic   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

5 fluorouracil; Cisplatin; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; High dose; Short course

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; LAMIVUDINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHOLANGITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 34250888086     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22759     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statics 2002. CA Cancer J Clin. 2005;55:74-108.
2. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
3. Llovert JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol. 2001;35:421-430.
5. Han KH, Lee JT, Seong J. Treatment of non-resectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17: S424-S427.
6. Bruix J, Llovert JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35: 519-524.
7. Seno H, Ito K, Kojima K, et al. Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. J Gastroenterol Hepatol. 1999;14:811-816.
8. Atiq OT, Kemeny N, Niedzwiecki D, Boter J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer. 1992;69:920-924.
9. Ahn SH, Han KH, Park JY, et al. Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). Yonsei Med J. 2004;45:847-858.
10. Miura T. Intraarterial infusion chemotherapy for advanced cancer-40 years of experience. Gan To Kagaku Ryoho. 2005; 32:1618-1622.
11. Murata K, Shiraki K, Kawakita T, et al. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res. 2003;23:1719-1722.
12. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997;79:1890-1896.
13. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588-595.
14. Itamoto T, Nakahara T, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J. Surg Oncol. 2002;80:143-148.
15. Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res. 2003;23:1891-1897.
16. Collins JM. Pharmacokinetic rationale for intraarterial therapy. In: Howell SB, editor. Intra-Arterial and Intracavitary Cancer Chemotherapy. Boston: Martinus Nijhoff Publishers; 1984:1-10.
17. Arai Y, Inaba Y, Takeuchi Y, Ariyoshi Y. Intermittent hepatic arterial infusion of high-dose 5-FU on a weekly schedule for metastases from colorectal cancer. Cancer Chemother Pharmacol. 1997;40:526-530.
18. Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005;40:70-78.
19. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of α -fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524-532.
20. Patt YZ, Yoffe B, Charnsangavej C, et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interieron-alpha-2b. Cancer. 1993;72:2574-2582.